<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616494</url>
  </required_header>
  <id_info>
    <org_study_id>HB1801-006</org_study_id>
    <nct_id>NCT05616494</nct_id>
  </id_info>
  <brief_title>A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer</brief_title>
  <official_title>A Single-arm, Multicenter, Phase Ⅱ Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer Who Have Received at Least One Line of Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a single-arm, multicenter clinical study to evaluate the efficacy and safety of&#xD;
      Docetaxel for Injection (Albumin-bound) in patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Simon two-stage design will be adopted in this study. In the first stage, 24 patients will be&#xD;
      enrolled, if at least 2 of them get response (CR or PR), the second stage of the study will&#xD;
      be conducted, and 29 additional patients will be enrolled. If there is only one or no&#xD;
      patients get response (CR or PR) in the first stage, the study will be early terminated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) by Independent Review Committee (IRC)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR by investigator</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) by IRC and investigator</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of Response (DoR) by IRC and investigator</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progression-Free-Survival (PFS) by IRC and investigator</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of AE and SAE</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentration of docetaxel (free and total)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel for Injection (Albumin-bound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel for injection (Albumin-bound)</intervention_name>
    <description>Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.</description>
    <arm_group_label>Docetaxel for Injection (Albumin-bound)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥18 years (subject to the date when the informed consent form is signed)&#xD;
             and voluntarily signed the informed consent form.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of pancreatic cancer.&#xD;
&#xD;
          3. Patients who have got disease progression or toxic intolerance after previous standard&#xD;
             treatment (gemcitabine based and fluorouracil based therapy).&#xD;
&#xD;
          4. At least one measurable lesion according to RECIST v1.1(the measurable lesion area had&#xD;
             not received previous radiation therapy or had evidence of definite progression after&#xD;
             the end of radiation therapy).&#xD;
&#xD;
          5. Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of&#xD;
             0-2.&#xD;
&#xD;
          6. Patients with estimated survival time of ≥ 3 months.&#xD;
&#xD;
          7. Patients with fine organ function (no medical supportive treatments such as blood&#xD;
             component transfusion, growth factors within 2 weeks before taking the relevant&#xD;
             inspections):&#xD;
&#xD;
             Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥100×10^9/L; Hemoglobin ≥90 g/L;&#xD;
             Albumin≥30 g/L; Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 40 mL/min;&#xD;
             Total bilirubin≤1.5 × ULN(≤ 2 × ULN for patients with obstructive jaundice, ≤3 × ULN&#xD;
             for patients with Gilbert's syndrome); Alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) ≤ 3× ULN (≤5× ULN for patients with liver metastasis);&#xD;
             Prothrombin time (PT) ≤ 1.5×ULN, International Normalized Ratio (INR) ≤ 1.5×ULN.&#xD;
&#xD;
          8. The patient must agree to take adequate contraception from signing of ICF through 6&#xD;
             months after last dose, women of childbearing potential (WOCBP) must have a negative&#xD;
             serum pregnancy test within 7 days prior to the first dose of the investigational&#xD;
             drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have a history of severe allergy to any excipients of the investigational&#xD;
             drug or taxanes.&#xD;
&#xD;
          2. Patients who had no response to previous taxanes treatments (no tumor shrinkage was&#xD;
             observed or disease progressed within 3 months after initiation of the treatment).&#xD;
&#xD;
          3. Patients with partial or complete intestinal obstruction or complete biliary&#xD;
             obstruction that cannot be relieved by active treatment.&#xD;
&#xD;
          4. Patients who had a history of other active malignant tumors within 2 years before the&#xD;
             first dose of the investigational drug, except for the study disease pancreatic cancer&#xD;
             and curable cancer that had been cured (such as basal cell or squamous cell skin&#xD;
             cancer, superficial bladder cancer, cervical cancer or breast cancer in situ that had&#xD;
             been excised).&#xD;
&#xD;
          5. Patients with brain metastases and meningeal metastases.&#xD;
&#xD;
          6. Patients with chronic hepatitis B (HBsAg and/or HBcAb positive but HBV DNA &lt; 2000&#xD;
             IU/mL can be included), chronic hepatitis C (HCV antibody positive but HCV RNA&#xD;
             negative can be included), and HIV antibody positive.&#xD;
&#xD;
          7. Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤&#xD;
             level 1 based on CTCAE 5.0 (except for alopecia, hyperpigmentation, or other toxicity&#xD;
             without safety risk judged by the investigator).&#xD;
&#xD;
          8. Patients with a history of severe cardiovascular disease, including but not limited&#xD;
             to:&#xD;
&#xD;
               1. Severe heart rhythm or conduction abnormalities, including but not limited to&#xD;
                  ventricular arrhythmia requiring clinical intervention and third degree&#xD;
                  atrioventricular block within 6 months before the first dose of the&#xD;
                  investigational drug;&#xD;
&#xD;
               2. History of myocardial infarction, unstable angina pectoris, angioplasty and&#xD;
                  coronary artery bypass surgery within 6 months before the first dose of the&#xD;
                  investigational drug;&#xD;
&#xD;
               3. Heart failure with New York Heart Association (NYHA) Classification of Class III&#xD;
                  and above;&#xD;
&#xD;
               4. Poorly controlled hypertension (Systolic blood pressure ≥ 160 mmHg and/or&#xD;
                  diastolic blood pressure ≥ 100 mmHg at screening period).&#xD;
&#xD;
          9. Patients with uncontrolled serous cavity effusion requiring frequent drainage or&#xD;
             medical intervention (e.g., pleural effusion, abdominal effusion, pericardial&#xD;
             effusion, etc., additional intervention was needed within 2 weeks after intervention,&#xD;
             excluding exfoliative cytology testing of the exudate) within 7 days before the first&#xD;
             dose of the investigational drug.&#xD;
&#xD;
         10. Patients with severe or active infections (including tuberculous infections) that&#xD;
             require systemic antibacterial, antifungal, or antiviral therapy within 14 days before&#xD;
             the first dose of the investigational drug, antiviral therapy for patients with viral&#xD;
             hepatitis is permitted.&#xD;
&#xD;
         11. Patients who have received anti-tumor treatments such as chemotherapy, targeted&#xD;
             therapy, immunotherapy and other clinical study drugs within 4 weeks or 5 half-lives&#xD;
             of the drugs (whichever is shorter) before the first dose of the investigational drug.&#xD;
&#xD;
         12. Patients who have used potent inhibitors or inducers of CYP3A4 within 2 weeks before&#xD;
             the first dose of the investigational drug.&#xD;
&#xD;
         13. Patients who have undergone major surgery within 4 weeks before the first dose of the&#xD;
             investigational drug and had not recovered sufficiently, or who need to undergo&#xD;
             elective surgery during the study.&#xD;
&#xD;
         14. Pregnant or nursing women.&#xD;
&#xD;
         15. Patients who is participating in another clinical study simultaneously unless it is an&#xD;
             observational (non-interventional) clinical study or within the follow-up period of an&#xD;
             interventional study.&#xD;
&#xD;
         16. Other situations that the investigator considers not suitable for participating in the&#xD;
             clinical study, including but not limited to: the patient is complicated by severe or&#xD;
             uncontrolled medical conditions, which will increase the safety risk, interfere with&#xD;
             the interpretation of study results or affect the study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xianju Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe zhang</last_name>
    <phone>13115039707</phone>
    <email>zhangzhe@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xianjun Yu, Doctor</last_name>
      <phone>+86-13801669875</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

